NASDAQ : ACRV
Acrivon Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 1.66 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 71.14M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 68.99M |
| Enterprise Value | -18.85M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 42.85M |
| Shares Outstanding | 42.85M |
| Shares Change (YoY) | +2.97% |
| Shares Change (QoQ) | +8.05% |
| Owned by Insiders (%) | 5.85% |
| Owned by Institutions (%) | 30.64% |
| Float | 25.83M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.82 |
| P/TBV Ratio | 0.82 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 7.99 |
| Quick Ratio | 7.86 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -64.63% |
| Return on Assets (ROA) | -38.02% |
| Return on Invested Capital (ROIC) | -41.67% |
| Return on Capital Employed (ROCE) | -89.42% |
| Weighted Average Cost of Capital (WACC) | 14.41% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$976,645 |
| Employee Count | 76 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.93 |
| 52-Week Price Change | -19.10% |
| 50-Day Moving Average | 1.93 |
| 200-Day Moving Average | 1.77 |
| Relative Strength Index (RSI) | 36.27 |
| Average Volume (20 Days) | 199,654 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 1.74M |
| Short Previous Month | 1.62M |
| Short % of Shares Out | 4.05% |
| Short % of Float | 6.73% |
| Short Ratio (days to cover) | 5.46 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -78.37M |
| Pretax Income | -74.23M |
| Net Income | -74.23M |
| EBITDA | -76.88M |
| EBIT | -78.37M |
| Earnings Per Share (EPS) | -$1.88 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 89.96M |
| Total Debt | 2.12M |
| Net Cash | 87.84M |
| Net Cash Per Share | $2.05 |
| Equity (Book Value) | 86.67M |
| Book Value Per Share | 2.02 |
| Working Capital | 80.05M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -62.92M |
| Capital Expenditures | -1.22M |
| Depreciation & Amortization | 1.50M |
| Net Borrowing | n/a |
| Free Cash Flow | -64.14M |
| FCF Per Share | -$1.50 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -2.97% |
| Shareholder Yield | -2.97% |
| Earnings Yield | -116.86% |
| FCF Yield | -90.71% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $11.50 |
| Price Target Difference | 614.29% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |